By Fineline Cube 
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), the China-based oncology specialist formerly known as BeOne Medicines Ltd., announced the termination of its clinical development program for ociperlimab (BGB-A1217), a TIGIT-targeted antibody. This decision follows the Independent Data Monitoring Committee’s (IDMC) recommendation to halt the Phase III AdvanTIG-302 study based on futility analysis results.
Clinical Trial Termination
The IDMC’s evaluation of the trial’s overall efficacy and safety data indicated that achieving the primary endpoint of overall survival was unlikely. Despite no new safety signals observed, the trial will be discontinued, marking a significant shift in BeiGene’s development strategy.
Novartis Licensing Deal
In December 2021, Novartis entered into a USD 2.895 billion licensing deal with BeiGene for ociperlimab. However, this collaboration was terminated in July 2023 following strategic reassessments and the evolving landscape of oncology treatments.-Fineline Info & Tech